595 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Acquired by PKS Advisory Services LLC

PKS Advisory Services LLC acquired a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 595 shares of the pharmaceutical company's stock, valued at approximately $240,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Prestige Wealth Management Group LLC lifted its stake in Vertex Pharmaceuticals by 45.5% in the fourth quarter. Prestige Wealth Management Group LLC now owns 112 shares of the pharmaceutical company's stock worth $45,000 after purchasing an additional 35 shares during the last quarter. TIAA Trust National Association boosted its holdings in Vertex Pharmaceuticals by 2.3% during the 4th quarter. TIAA Trust National Association now owns 5,763 shares of the pharmaceutical company's stock valued at $2,321,000 after acquiring an additional 131 shares during the period. Ashton Thomas Securities LLC grew its position in Vertex Pharmaceuticals by 1.7% during the 4th quarter. Ashton Thomas Securities LLC now owns 3,244 shares of the pharmaceutical company's stock worth $1,306,000 after acquiring an additional 55 shares during the last quarter. Princeton Capital Management LLC boosted its stake in shares of Vertex Pharmaceuticals by 0.4% during the fourth quarter. Princeton Capital Management LLC now owns 15,174 shares of the pharmaceutical company's stock valued at $6,111,000 after purchasing an additional 64 shares during the period. Finally, EFG Asset Management North America Corp. grew its holdings in shares of Vertex Pharmaceuticals by 49.0% in the fourth quarter. EFG Asset Management North America Corp. now owns 12,055 shares of the pharmaceutical company's stock worth $4,856,000 after purchasing an additional 3,964 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors.

Remove Ads

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ VRTX traded down $9.86 during trading on Friday, reaching $492.69. 1,280,587 shares of the company traded hands, compared to its average volume of 1,275,535. The firm has a 50 day simple moving average of $476.45 and a 200-day simple moving average of $463.71. Vertex Pharmaceuticals Incorporated has a 52-week low of $377.85 and a 52-week high of $519.88. The stock has a market capitalization of $126.52 billion, a PE ratio of -223.95, a P/E/G ratio of 2.11 and a beta of 0.41. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing analysts' consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. Equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Wall Street Analyst Weigh In

VRTX has been the topic of a number of analyst reports. Barclays boosted their price objective on shares of Vertex Pharmaceuticals from $435.00 to $467.00 and gave the company an "equal weight" rating in a research report on Tuesday, February 11th. JPMorgan Chase & Co. reduced their target price on Vertex Pharmaceuticals from $503.00 to $500.00 and set an "overweight" rating on the stock in a research note on Monday, December 23rd. Stifel Nicolaus lifted their price target on shares of Vertex Pharmaceuticals from $490.00 to $494.00 and gave the company a "hold" rating in a report on Monday, December 16th. Cantor Fitzgerald restated an "overweight" rating and issued a $480.00 price objective on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. Finally, StockNews.com raised shares of Vertex Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Tuesday, March 11th. Ten investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $506.70.

Insider Activity at Vertex Pharmaceuticals

In other news, EVP David Altshuler sold 3,231 shares of the company's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the completion of the sale, the executive vice president now owns 26,512 shares of the company's stock, valued at $13,256,000. This represents a 10.86 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Ourania Tatsis sold 530 shares of the stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $475.34, for a total transaction of $251,930.20. Following the completion of the transaction, the executive vice president now owns 58,539 shares in the company, valued at $27,825,928.26. This trade represents a 0.90 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 4,315 shares of company stock worth $2,121,012. 0.20% of the stock is owned by insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.